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Abstract
The purpose of this study was to explore the use of iterative decomposition of water and fat with echo asymmetry and least-squares estimation
Carr–Purcell–Meiboom–Gill (IDEAL-CPMG) to simultaneously measure skeletal muscle apparent fat fraction and water T2 (T2,w) in patients with
Duchenne muscular dystrophy (DMD). In twenty healthy volunteer boys and thirteen subjects with DMD, thigh muscle apparent fat fraction was
measured by Dixon and IDEAL-CPMG, with the IDEAL-CPMG also providing T2,w as a measure of muscle inflammatory activity. A subset of
subjects with DMD was followed up during a 48-week clinical study. The study was in compliance with the Patient Privacy Act and approved by
the Institutional Review Board. Apparent fat fraction in the thigh muscles of subjects with DMD was significantly increased compared to healthy
volunteer boys (p < 0.001). There was a strong correlation between Dixon and IDEAL-CPMG apparent fat fraction. Muscle T2,w measured by
IDEAL-CPMG was independent of changes in apparent fat fraction. Muscle T2,w was higher in the biceps femoris and vastus lateralis muscles of
subjects with DMD (p < 0.05). There was a strong correlation (p < 0.004) between apparent fat fraction in all thigh muscles and six-minute walk
distance (6MWD) in subjects with DMD. IDEAL-CPMG allowed independent and simultaneous quantification of skeletal muscle fatty
degeneration and disease activity in DMD. IDEAL-CPMG apparent fat fraction and T2,w may be useful as biomarkers in clinical trials of DMD as
the technique disentangles two competing biological processes.
Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
Promising new treatments for Duchenne muscular dystrophy
(DMD) are now being studied in clinical trials [1]. There is
an urgent need for biomarkers to assess disease activity
and treatment response in DMD. Since the disease pathology
and treatment response may vary locally within a muscle,
biomarkers that reflect the spatial distribution of the disease
process within and across muscles are desired. Magnetic
resonance imaging (MRI) enables non-invasive, repeatable, and
objective assessment of individual muscles. In a preliminary
study, muscle fat fractions quantified by Dixon correlated better
with functional scores than measures of muscle strength [2].
Skeletal muscle T2 relaxation times were described as a
biomarker of disease progression [3,4] and treatment response
in patients [5] and animal models of DMD [6]. However,
increases in lipids and extracellular water contribute to
lengthening of the apparent skeletal muscle T2, therefore the
effects of inflammatory activity cannot be distinguished from
fatty infiltration. Absence of muscle fat in mouse models
makes apparent T2 and water T2 measurements almost
equivalent [7]. In contrast increases in apparent T2 in patient
muscle are proportional to increase in muscle fat fraction,
and provide little information on inflammatory activity [7–9].
Simultaneous measurements of T2-weighted fat and
T2-weighted water images independently within a single
acquisition make iterative decomposition of water and fat with
echo asymmetry and least-squares estimation Carr–Purcell–
Meiboom–Gill (IDEAL-CPMG) an attractive MRI technique
for measuring inflammatory disease activity in the presence of
fatty degeneration [7,10]. The present study explored the use of
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IDEAL-CPMG in assessing disease activity in subjects with
DMD participating in a clinical trial.
2. Materials and methods
2.1. Participants and study design
The DMD Imaging Study was a 48-week prospective
imaging study conducted between January 2012 and October
2013 as an optional sub-study of a multi-center phase 2, double
blind, placebo-controlled trial of oligonucleotide therapy
in ambulatory boys with DMD resulting from a mutation
potentially corrected by skipping exon 51 (DMD114876;
NCT01462292). The DMD imaging study was offered to all
subjects eligible for the DMD114876 study before or during
their first screening visit. Appendix E1 (online) contains details
of subject eligibility, recruitment, and inclusion and exclusion
criteria. Subjects in the larger study received either drisapersen
(3 or 6 mg/kg/week) or placebo for 24 weeks followed by a
24-week post-treatment phase. The subjects traveled to our
Clinical Center during the screening phase, and at 12, 24, and
48 weeks. Subjects not eligible for randomization in the clinical
trial had a one-time evaluation during the screening phase. Pilot
data were also obtained from age-range matched healthy
volunteer (HV) boys who were recruited from our Clinical
ResearchVolunteer Program registry.All subjects were asked to
avoid any excessive physical activity beyond their normal levels
for a week prior to each study visit.
2.2. Standard protocol approvals, registrations, and
patient consents
The study was registered on clinicaltrials.gov
(NCT01451281) and was in compliance with the Patient
Privacy Act and approved by the Institutional Review Board.
Informed written assent and consent were obtained from the
subject and parent or guardian before participation in the study.
2.3. MRI acquisition
MR images included a T1-weighted scan, an IDEAL-CPMG
scan, and a DIXON scan acquired on a 3T Verio scanner
(Siemens, Erlangen, Germany) at the Clinical Center. A
Siemens 8 channel Body Matrix Coil Array was used for the
thighs. All scans were performed on the same scanner. A parent
or staff member was present in the scanner suite to alleviate
subject anxiety. MR operators were trained to ensure
consistency in the image acquisition across study visits.
Imaging was performed at mid-thigh, defined on the right
femur as the midpoint between the inferior edge of the
right medial femoral condyle and the inferior edge of the
right femoral head. T1-weighted turbo spin echo images
were acquired consisting of 21 5 mm slices with 5 mm gap
and 1.5 mm in-plane resolution. The IDEAL-CPMG [10]
acquisition measured 3 gradient echoes around each of N =12
spin echo times (10 ms, 20 ms, . . .,120 ms). The gradient
echoes sampled three fat-water shifts at (−5π/6, π/2, 11π/6)
[11] around each spin-echo time. Sixteen 5 mm slices with
5 mm gap were imaged in a 40 × 20 cm FOV with matrix size
of 160 × 80, resulting in 2.5 × 2.5 × 5 mm voxel size with a TR
of 5 s, resulting in a scan time of 6 m: 45 s. The Dixon
acquisition consisted of 2 gradient echoes at 2.45 and 3.675 ms
(nominally in-phase and out-of-phase at 3T) with a B0 field
map in a 24 cm 3D slab with 48 5 mm sections in a 36 × 25 cm
FOV with 256 × 256 matrix size, resulting in 1.4 × 1.4 × 5 mm
voxels. The Dixon scan used a TR of 5.64 ms, flip angle 9°, and
2 averages in each of two abutting 3D slabs, resulting in 1 m:
40 s scan time.
2.4. MRI analysis
The T1-weighted scans were used as an anatomical reference
image for the co-registration of all other within-visit scans
for a given subject and for definition of the six thigh muscle
regions-of-interest (ROIs): bicep femoris, rectus femoris,
semitendinosus, vastus intermedius, vastus lateralis, and vastus
medialis in the central five imaging slices of the right leg
covering a distance of 50 mm. Definition of these muscle
groups was performed manually using the Analyze 11.0
software package (AnalyzeDirect, Overland Park, KS). The
co-registration process was a rigid-body (six degrees of
freedom) transformation using the FSL tool FLIRT [12]. For
two scans (one baseline and one 24-week scan), the T1-weighted
image was incomplete/unusable, so the in-phase Dixon scan
was instead used as the anatomical reference image.
Dixon images were reconstructed using Siemens (Erlangen,
Germany) product software producing a single water image ( sw)
and fat image ( s f ) generated from two gradient echo images and
a fieldmap [13].The apparent fat fraction (AFF) measured using
Dixon was then calculated as AFF s s sDixon f f w= ∗ +( )100 .
IDEAL-CPMG was reconstructed using in-house MATLAB
code to generate a n N=1… series of T2-weightedwater images,
ρw n[ ] , and T2-weighted fat images, ρ f n[ ]. The water proton
density (ρ0,w), fat proton density (ρ0, f ), T2 of water (T w2, ), T2 of
fat (T f2, ), were then fit according to ρ ρw wn ms[ ] = −(0 10, exp
w wn T N⋅ ) +2, and ρ ρf f f fn ms n T N[ ] = − ⋅( ) +0 210, ,exp where
Nw and N f account for the non-zero floor due to sequence
imperfections (e.g. B1-inhomogeneity, stimulated echoes) and
the noise floor of magnitude data [14]. The T2-corrected
AFF measured using IDEAL-CPMG was then calculated as
AFFIDEAL CPMG f f w− = ∗ +( )100 0 0 0ρ ρ ρ, , , . Full details of the
reconstruction and fitting can be found elsewhere [10].
For both the Dixon and the IDEAL-CPMG sequences, the
reconstructed in-phase image was used for co-registration
to the corresponding T1-weighted scan, with the computed
co-registration parameters subsequently used to transform all of
the remaining maps for that given imaging sequence (i.e., the T2
maps (T2,w, T2,f) and AFFmaps for IDEAL-CPMG, and the AFF
maps for Dixon). For each of the processed maps the mean of
the signal in each of the muscle ROIs was generated using
in-house MATLAB functions. All investigators were blinded to
subject grouping and treatment during analysis.
2.5. Statistical analysis
A two-sample t-test, nonparametric (Mann–Whitney) test,
and Fisher’s z transformation of sample correlation coefficients
were used in cross-sectional comparisons. The level of
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significance was set at p < 0.05 without corrections for multiple
comparisons. The degree of agreement was measured by the
Bland–Altman method [15]. Pearson’s correlation was used for
continuous variables. Spearman’s rank correlation was used for
ordinal variables. Data analyses were done using Prism 6.0
(Graphpad Software, La Jolla, CA, USA).
3. Results
3.1. Subject characteristics
Baseline MRI data were obtained from 13 boys with DMD
and 20 HV boys. Both groups were similar in age (DMD:
6–14 years; mean ± SD: 8.8 ± 2.4 years; and HV: 5–14 years;
mean ± SD: 10 ± 2.1 years; p = 0.13) and age-adjusted height
(p = 0.06) and weight (p = 0.17). Nine subjects with DMD,
who were randomized to drisapersen 3 mg/kg/week (n = 6) or
placebo (n = 3), returned for follow up visits at 12, 24, and 48
weeks during the DMD114876 trial. Three subjects did not
have follow up visits because they were not randomized in the
clinical trial, and one subject withdrew from the study after the
baseline visit due to family/personal reasons.
3.2. Thigh muscle apparent fat fraction (AFF) and water
T2 (T2,w) in age-range matched healthy volunteers and
subjects with Duchenne muscular dystrophy (DMD)
Fig. 1 shows a T1-weighted image and IDEAL-CPMG
images including T2-corrected AFF map and T2,w map from
representative slices in three subjects with DMD. A variable
degree of fatty replacement is seen in all subjects, but edema is
less prominent and seen in isolated muscle groups in a subset of
subjects (white arrow) on the T2,w map.
The AFF in six thigh muscles measured by IDEAL-CPMG
and Dixon was about 2 to 4 fold higher in subjects with DMD
than the age-range matched HV boys (Fig. 2A and B, Table 1).
A linear regression model using factor status, HV or DMD, and
age as a covariate showed a significantly higher AFF in subjects
with DMD compared to HV boys at all ages (p ≤ 0.001). The
range of Dixon AFF in the thigh muscles was 4%–17% in HV
boys and 8%–75% in subjects with DMD and that of IDEAL-
CPMG AFFwas 3%–20% in HV boys and 7%–84% in subjects
with DMD (Table 1). There was a strong correlation between
IDEAL-CPMG and Dixon for AFF measurements in the same
muscle (n = 180 muscles, Spearman r = 0.92; p < 0.0001). The
Fig. 1. Representative T1-weighted and IDEAL-CPMG images of the thigh muscles in three subjects with Duchenne muscular dystrophy (DMD). A T1-weighted
image (A), T2-corrected fat fraction map (B), and water-T2 map (C) are shown representing subject anatomy, changes in muscle apparent fat fraction (AFFIDEAL-CPMG)
and muscle water T2 (T2,w IDEAL-CPMG) respectively in the thigh muscles of subjects with DMD.A different severity of fatty degeneration is present in the thigh muscles
of each subject, whereas inflammatory activity is sparse and seen in only few muscles (arrow).
Table 1
MRI measures of muscle apparent fat fraction (AFF) in the thigh muscles of age-range matched healthy volunteers (HV) and subjects with Duchenne muscular
dystrophy (DMD).
Muscles IDEAL-CPMG
Median AFF (%) (range)
Dixon
Median AFF (%) (range)
HV (n = 14) DMD (n = 10) p value Mann–Whitney HV (n = 16) DMD (n = 8) p value Mann–Whitney
Biceps femoris 7.4 (4.2–17.5) 23.5 (16.4–80.8) <0.0001 10.5 (5.1–15.8) 23.0 (17.3–74.7) <0.0001
Rectus femoris 6.5 (4.1–20.3) 28.2 (11.8–84.0) <0.0001 6.6 (3.6–11.7) 20.2 (13.4–71.7) <0.0001
Semitendinosus 8.3 (4.1–19.6) 19.1 (11.8–49.9) <0.001 8.1 (5.1–13.3) 15 (13.6–40.2) <0.0001
Vastus intermedius 3.6 (3–10.1) 15.1 (7.3–79.4) <0.001 7 (4.8–10.7) 15.5 (8.5–74) <0.0001
Vastus lateralis 5.2 (3.9–17.5) 18.3 (8.3–83.9) <0.001 11 (5.7–17.4) 18.8 (11.4–75.4) <0.001
Vastus medialis 5 (3.8–19.7) 17.9 (8.0–80.5) <0.001 6.7 (4.8–11.4) 14.1 (9.9–72.3) <0.0001
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mean difference, IDEAL-CPMG minus Dixon, was 0.95 (95%
CI 0.29, 1.63). Fig. 2C and D show agreement between the
two methods. Bland and Altman plot shows that 95% of the
differences in the AFF were within the limits of agreement
(−7.97, 9.88) (Fig. 2D). We found significant correlations
among all muscles of subjects with DMD for IDEAL-CPMG
and Dixon AFF (Table 2).
The IDEAL-CPMG T2,w of the biceps femoris
(mean ± S.E.M 31.4 ± 0.4 v. 29.9 ± 0.5; p = 0.02) and vastus
lateralis (mean ± S.E.M 32.3 ± 0.4 v. 31.3 ± 0.7; p = 0.03)
muscles was significantly higher in subjects with DMD
than HV boys (Fig. 2E, Table 3). The T2,w of other muscles
was not significantly different between the two groups. There
was no correlation between IDEAL-CPMG T2,w and AFF in
the same muscle (n = 240 muscles, Spearman r = 0.04;
p = 0.48) (Fig. 2F).
3.3. Age correlations with thigh muscle IDEAL-CPMG AFF
and T2,w in subjects with DMD
The AFF of the biceps femoris, vastus medialis, vastus
intermedius and vastus lateralis muscles increased with
age in subjects with DMD (Pearson r = 0.65–0.69; p < 0.05)
(Fig. 3A). There was no significant correlation between age
and AFF in the rectus femoris and semitendinosus muscles
(Pearson r = 0.53–0.54; p = 0.1). The T2,w decreased with age
in the rectus femoris muscle (Pearson r = −0.67, p < 0.05),
whereas there was no significant correlation in the other
muscles (Pearson r = −0.56–0.04; p = 0.09–0.4) of subjects
with DMD (Fig. 3B). No correlations were found between age
and the muscle AFF or T2,w in HV boys.
MRI scans were evaluated in 4 subjects with DMD
randomized to drisapersen at 3 mg/kg/week (age range: 7–10
years) and 2 subjects (age: 6 years) randomized to placebo at
baseline, 24 weeks, and 48 weeks during the DMD114876 trial.
Fig. 2. MRI quantification of thigh muscle apparent fat fraction (AFF) and water T2 (T2,w) in age range-matched healthy volunteers (HV) and subjects with Duchenne
muscular dystrophy (DMD). (A,B) Comparison of AFF measured by Dixon (A) and IDEAL-CPMG (B) in the biceps femoris (BF), rectus femoris (RF),
semitendinosus (ST), vastus intermedius (VI), vastus lateralis (VL), and vastus medialis (VM) muscles of HV boys (blue circles) and subjects with DMD (red
squares). Mean AFF measured by both methods was significantly higher in all the muscles in subjects with DMD relative to HV (p < 0.001). (C,D) Line of identity
(C) and Bland–Altman plot (D) demonstrate excellent agreement between the two methods. Difference = AFFIDEAL-CPMG – AFFDixon. Dotted lines in D represent mean
difference and limits of agreement (mean ± 1.96 S.D.) (E) Mean T2,w values were significantly higher in the BF (p = 0.02) and VL (p = 0.03) of subjects with DMD
(red squares) relative to HV boys (blue circles). (F) Graph shows that T2,w measurements were independent of the variation in AFF in 240 muscles examined in HV
boys (blue circles) and subjects with DMD (red squares). Error bars represented as mean ± SEM.
Table 2
Spearman correlations between muscle AFF IDEAL-CPMG (a) and AFF Dixon (b) in
six thigh muscles of subjects with Duchenne muscular dystrophy (DMD).
(a)
Muscles BF RF ST VI VL VM
BF 1 0.73* 0.74* 1**** 0.94*** 0.91***
RF 1 0.65 0.73* 0.81** 0.81**
ST 1 0.74* 0.83** 0.88**




Muscles BF RF ST VI VL VM
BF 1 0.90* 0.69 0.90** 0.90** 0.90**
RF 1 0.40 0.76* 0.71 0.71
ST 1 0.79* 0.74 0.74
VI 1 0.95** 0.95**
VL 1 1***
VM 1
* p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001.
BF = biceps femoris, RF = rectus femoris, ST = semitendinosus, VI = vastus
intermedius, VL = vastus lateralis, VM = vastus medialis.
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Images in the remaining 3 subjects were not suitable for
quantitative longitudinal analysis due to motion artifacts or
fat/water swaps across ROIs. The AFF of the thigh muscles
ranged from 45% to 76% in the 10 year old subject and ≤ 25%
in the younger subjects. The six year-old subjects (n = 2) in the
placebo group had ≤ 2% increase in mean muscle AFF,
whereas the 7–10 year old subjects (n = 4) assigned to treatment
group had ≥ 6% increase in mean muscle AFF of the thigh
muscles during the 48-week follow up. The T2,w range (29–
44 ms) in the thigh muscles was not different between the
subjects in the placebo and treatment groups. There was no
apparent effect of the treatment on AFF or T2,w in this cohort.
3.4. Correlations between six-minute walk distance and thigh
muscle AFFIDEAL-CPMG in subjects with DMD
All subjects showed a change in the six-minute walk distance
(6MWD) over the 48-week period (Fig. 4A). The six and seven
year-old subjects had an increase in the 6MWD, whereas DMD
subjects age >7 years had a decline in the 6MWD, as shown
previously [16]. There was an exception in that the seven year-old
subject had a lower 6MWD relative to the eight year-old subject
throughout the study period. Notably, the seven year-old subject
had a higher AFF in all six muscles compared to the eight-year
old subject. We observed that changes in AFF of the thigh
muscles over time had a trend opposite to that of the 6MWD
in younger vs. older subjects with DMD (Fig. 4B; vastus lateralis
muscle shown). We examined correlations between all available
paired measurements of AFF in individual thigh muscles and
6MWD in subjects with DMD (n = 22 for each muscle; each
pair was treated independently). Strong negative correlations
were found between the 6MWD and AFF in all thigh muscles
of subjects with DMD examined in this study (Spearman
r = −0.75 to −0.57; p ≤ 0.004) (Fig. 4C; vastus lateralis muscle
shown). Subjects with ≤ 20% AFF in the vastus lateralis muscle
walked > 400 m and conversely, those with > 20% AFF in the
vastus lateralis muscle walked < 400 m in 6 minutes.
The progression of muscle AFF (as in Ref. [17]) and muscle
water T2 was different in individual thigh muscles followed over
the 48-week period (Fig. 4D and E). In agreement with a recent
publication [18], we found that the IDEAL-CPMG sequence
detected modest increases in the thigh muscles AFF in the six
and seven year-old subjects whose 6MWD improved over the
year (Fig. 4D). The greatest increase (>10%) in the muscle AFF
was found in the biceps femoris and vastus lateralis muscles of
the eight and nine year-old subjects whose 6MWD declined by
>30 m (Fig. 4E). Overall, there was a greater increase in the
muscle AFF in the older subjects whose 6MWD decreased
compared to the younger subjects whose 6MWD increased
during the 48-week follow up period. Conversely, the changes
in muscle water T2 were more remarkable in the younger
subjects with increased 6MWD compared to the older subjects
with decreased 6MWD over the year (Fig. 4D and E).
4. Discussion
Quantitative MRI correlates of fatty degeneration and
muscle inflammatory activity are potentially useful for
monitoring disease progression and treatment response during
a clinical trial. The MRI parameter of muscle inflammatory
activity corresponds to water mobility within muscle tissue
(T2,w) and may reflect loss of muscle fiber integrity in the
dystrophic lesions and in the areas of inflammation and necrosis
in skeletal muscle. Changes in T2,w are dynamic and sensitive to
the underlying disease activity. Fatty replacement of muscle
tissue occurs during later stages in the disease process. Dixon
separates muscle fat and water based on phase difference
(chemical shift) and provides measurement of muscle fat
without any confounding effect of muscle edema. However,
quantification of muscle inflammatory activity in fat-infiltrated
dystrophic muscles has been challenging because increases
in muscle water T2 are masked by the presence of muscle
fat [7,9]. We present IDEAL-CPMG as an MRI biomarker for
simultaneous quantification of skeletal muscle T2,w and AFF
in DMD. Our results show that IDEAL-CPMG reliably and
efficiently separates fat and water components of T2 in the thigh
muscles, which are affected early and more severely than other
muscles in subjects with DMD. There was no relationship
between T w2, and AFF (r = 0.04), indicating that there is little
fat contamination within the IDEAL-CPMG water signal and
that the level of inflammatory activity does not change with
increases in AFF in the thigh muscles of subjects with DMD.
This agrees with previous studies in DMD using spectroscopy
in the lower leg muscles [3] and the forearm muscles [19] but
contrasts to previous studies in hypokalemic periodic paralysis
[20] where a weak correlation (r = 0.54) between T w2, and AFF
in the lower leg muscles was observed.
MR spectroscopy (MRS) is the standard for noninvasive
measurement of muscle fat. However, poor spatial resolution
and coverage as well as challenges in the spectroscopy volume
registrations consistently between imaging visits limit its use
in multicenter clinical studies. IDEAL-CPMG and Dixon provide
better spatial resolution and coverage, enabling assessment of
multiple muscles simultaneously [10,21–23]. This is pertinent
in DMD because the disease varies locally within a muscle
and between muscles in patients. Variations of Dixon have
been used in AFF quantification in DMD [2,22,24,25]. We
observed a strong correlation (r = 0.92) between IDEAL-CPMG
and Dixon across a broad range (3%–84%) of muscle fat values.
The Dixon sequence is T1-weighted, with the level of fat
Table 3
MRI measures of water T2 (T2,w) in the thigh muscles of age-range matched
healthy volunteers (HV) and subjects with Duchenne muscular dystrophy
(DMD).
Muscles IDEAL-CPMG
Median muscle T2,w (ms) (range)
HV (n = 14) DMD (n = 10) p value
Mann–Whitney
Biceps femoris 29.6 (27.6–33.6) 31.1 (29.7–33.6) 0.02*
Rectus femoris 38.8 (28.2–63.1) 34.5 (29.4–44.2) 0.6
Semitendinosus 28.3 (26.7–32.6) 29.6 (28.1–34.3) 0.2
Vastus intermedius 31.1 (28.9–40.6) 31.7 (30.0–33.5) 0.1
Vastus lateralis 30.5 (28.7–39.2) 32.3 (30.4–34.2) 0.03*
Vastus medialis 34.8 (30.3–39.5) 32.8 (30.1–38.1) 0.1
* p < 0.05.
654 A. Mankodi et al. /Neuromuscular Disorders 26 (2016) 650–658
overestimated from the shorter T1 of fat versus water. The
IDEAL-CPMG sequence did not suffer from T1 saturation, but
a magnetization transfer effect from the radiofrequency pulses
would reduce only the water signal. Thus, both methods suffer
from reduction of the water signal, but for different reasons.
Further, the IDEAL-CPMG decomposition used a 7-peak fat
multispectral model [10], whereas the Dixon formulation assumes
a single fat peak. The implicit assumption of a single T2*
value in the Dixon sequence may explain the increased difference
between IDEAL-CPMG and Dixon at high fat fractions [26].
The AFF and T2,w changes had a different muscle pattern and
evolution with age in subjects with DMD. Fatty degeneration
Fig. 3. Age correlations with thigh muscle IDEAL-CPMG apparent fat fraction (AFF) and water T2 (T2,w) in subjects with Duchenne muscular dystrophy (DMD).
(A) There is a significant increase in AFF of the biceps femoris, vastus intermedius, vastus lateralis and vastus medialis muscles with age. (B) Conversely, there is
a significant decrease in T2,w of the rectus femoris muscle with age. Pearson correlation coefficient (r) is shown. Dotted lines represent mean values of the age-range
matched HV boys.
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was prominent and dystrophic inflammation or edema was
relatively sparse in the thigh muscles of the DMD cohort with
11 of 13 subjects ≥ 7 years of age. The biceps femoris and
vastus lateralis muscles were most responsive to disease
progression consistent with previous observations [3,18]. The
change in the T2,w of the thigh muscles was relatively less in the
>7 year-old subjects compared to younger ones. These findings
support previous observations that MRS T2,w may be a sensitive
marker of response to prednisone before skeletal muscles are
loaded with fatty degeneration [5] and that MRS T2,w tends to
normalize with disease progression in DMD [3,19]. The T2,w
was reliably measured in the hamstrings and vastus muscles (SE
±0.5 ms to ±0.8 ms). However, B1 inhomogeneity due to the
relatively high contribution from stimulated echoes within the
rectus femoris muscle precluded accurate T2,w assessment (SE
±2.4 ms). This could be addressed by using extended phase
graph fitting as proposed by Lebel and Wilman [27,28] instead
of the monoexponential least squares fitting employed in this
study. Other methodological limitations include a restricted
spatial resolution demanded by time constraints in a pediatric
study, and a simplistic fitting model for T2 decay in magnitude
images [29]. Further studies are needed to more fully qualify
these biomarkers, including determining the inter- and intra-
rater and site variability.
We did not see a therapeutic response to drisapersen on MRI
measures of fatty infiltration and edema in this exploratory
imaging substudy, probably because (1) few subjects
participated, (2) subjects receiving placebo and active agent had
Fig. 4. Change in the six-minute walk distance (6MWD) and thigh muscle IDEAL-CPMG apparent fat fraction (AFF) and water T2 (T2,w) in subjects with Duchenne
muscular dystrophy (DMD) from baseline to 48 weeks (including 24-week treatment phase plus 24-week follow up) in the clinical trial. (A,B) Change in the 6MWD
and the vastus lateralis muscle AFF from baseline to 48 weeks. The 6MWD increased in the six (light or dark blue) and seven (green) year-old subjects and decreased
in the eight (brown), nine (purple) and 10 (red) year-old subjects (A). Dotted lines represent predictor cutoffs of decline in ambulation (age > 7 years and
6MWD < 350 m) [16]. The vastus lateralis muscle AFF increased in all subjects (B). Dotted line represents the mean AFF of the age-range matched HV boys. Time
scale is shown from individual subject’s age at baseline. (C) Correlation between paired measurements of the 6MWD and the vastus lateralis muscle AFF. Spearman
r is shown. Dotted horizontal line represents mean AFF of the age-range matched HV boys (7.5%) and dotted vertical line represents predictor cutoff of decline in
ambulation (6MWD <350 m). (D,E) Change in muscle AFF and T2,w of the biceps femoris (BF), rectus femoris (RF), semitendinosus (ST), vastus intermedius (VI),
vastus lateralis (VL) and vastus medialis (VM) muscles of subjects with increased 6MWD (D) and decreased 6MWD (E). Each bar represents an individual subject
with color schema as in A and B.
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different age distributions due to randomization and (3) no
subjects received the higher dose (6 mg/kg/week) found to be
efficacious elsewhere [30], again due to randomization.
Our findings support the conclusions of earlier studies [18,31]
that MRI measures are sensitive to disease progression that
cannot be identified by functional testing such as 6MWD. We
found that subjects with DMD who walked about 350 m at
baseline had a broad range of AFF in each muscle. The 6MWD
and other functional assessments are influenced by patient
motivation and cooperation, which may be challenging in a
pediatric population. Furthermore, multiple muscle groups
differently affected by the disease are recruited during the
activity. In contrast, MRI biomarkers provide objective assessments
of individual muscles to monitor disease progression and treatment
response during clinical trial. Skeletal muscle AFF at baseline
in subjects with DMD may serve as an objective indicator of
disease severity and help to select or stratify subjects appropriately
for clinical trials.
In summary, IDEAL-CPMG provides independent and
simultaneous quantification of disease activity and fatty
degeneration in multiple skeletal muscles of subjects with
DMD. The T2,w changes are sparse in the thigh muscles of this
age group in DMD, agreeing with MRS [3,19] and in contrast
with apparent muscle T2 relaxation times [3,4]. IDEAL-CPMG
and Dixon agree well on AFF measurements. IDEAL-CPMG
AFF and T2,w may be useful as an imaging biomarker in future
trials.
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Abbreviations
IDEAL-CPMG iterative decomposition of water and fat with echo
asymmetry and least-squares estimation
Carr–Purcell–Meiboom–Gill
AFF apparent fat fraction
T2,w water T2
DMD Duchenne muscular dystrophy
MRI magnetic resonance imaging
MRS magnetic resonance spectroscopy
ROI region of interest
6MWD six-minute walk distance
References
[1] Seto JT, Bengtsson NE, Chamberlain JS. Therapy of genetic
disorders-novel therapies for Duchenne muscular dystrophy. Curr Pediatr
Rep 2014;2:102–12.
[2] Wren TA, Bluml S, Tseng-Ong L, Gilsanz V. Three-point technique of fat
quantification of muscle tissue as a marker of disease progression in
Duchenne muscular dystrophy: preliminary study. AJR Am J Roentgenol
2008;190:W8–12.
[3] Forbes SC, Willcocks RJ, Triplett WT, et al. Magnetic resonance imaging
and spectroscopy assessment of lower extremity skeletal muscles in boys
with Duchenne muscular dystrophy: a multicenter cross sectional study.
PLoS ONE 2014;9:e106435.
[4] Willcocks RJ, Arpan IA, Forbes SC, et al. Longitudinal measurements of
MRI-T2 in boys with Duchenne muscular dystrophy: effects of age and
disease progression. Neuromuscul Disord 2014;24:393–401.
[5] Arpan I, Willcocks RJ, Forbes SC, et al. Examination of effects of
corticosteroids on skeletal muscles of boys with DMD using MRI and
MRS. Neurology 2014;83:974–80.
[6] Walter G, Cordier L, Bloy D, Sweeney HL. Noninvasive monitoring
of gene correction in dystrophic muscle. Magn Reson Med 2005;
54:1369–76.
[7] Carlier PG. Global T2 versus water T2 in NMR imaging of fatty infiltrated
muscles: different methodology, different information and different
implications. Neuromuscul Disord 2014;24:390–2.
[8] Azzabou N, Loureiro de Sousa P, Caldas E, Carlier PG. Validation of a
generic approach to muscle water T2 determination at 3T in fat-infiltrated
skeletal muscle. J Magn Reson Imaging 2015;41:645–53.
[9] Hollingsworth KG. Quantitative MRI in muscular dystrophy: an
indispensable trial endpoint? Neurology 2014;83:956–7.
[10] Janiczek RL, Gambarota G, Sinclair CD, et al. Simultaneous T(2)
and lipid quantitation using IDEAL-CPMG. Magn Reson Med 2011;
66:1293–302.
[11] Pineda AR, Reeder SB, Wen Z, Pelc NJ. Cramer-Rao bounds for
three-point decomposition of water and fat. Magn Reson Med 2005;
54:625–35.
[12] Jenkinson M, Smith S. A global optimisation method for robust affine
registration of brain images. Med Image Anal 2001;5:143–56.
[13] Jellus V. Phase correction method. US Patent US20100201364, Aug 12,
2010.
[14] Milford D, Rosbach N, Bendszus M, Heiland S. Mono-exponential fitting
in T2-relaxometry: relevance of offset and first echo. PLoS ONE
2015;10:e0145255.
[15] Bland JM, Altman DG. Statistical methods for assessing agreement
between two methods of clinical measurement. Lancet 1986;1:307–
10.
[16] McDonald CM, Henricson EK, Abresch RT, et al. The 6-minute walk test
and other endpoints in Duchenne muscular dystrophy: longitudinal
natural history observations over 48 weeks from a multicenter study.
Muscle Nerve 2013;48:343–56.
[17] Hollingsworth KG, Garrood P, Eagle M, Bushby K, Straub V. Magnetic
resonance imaging in duchenne muscular dystrophy: longitudinal
assessment of natural history over 18 months. Muscle Nerve 2013;
48:586–8.
657A. Mankodi et al. /Neuromuscular Disorders 26 (2016) 650–658
[18] Willcocks RJ, Rooney WD, Triplett WT, et al. Multicenter prospective
longitudinal study of magnetic resonance biomarkers in a large duchenne
muscular dystrophy cohort. Ann Neurol 2016;79:535–47.
[19] Wary C, Azzabou N, Giraudeau C, et al. Quantitative NMRI and NMRS
identify augmented disease progression after loss of ambulation in
forearms of boys with Duchenne muscular dystrophy. NMR Biomed
2015;28:1150–62.
[20] Sinclair CD, Morrow JM, Janiczek RJ, et al. Reproducibility and
sensitivity of muscle-water T2 determined independendtly of fat fraction
with IDEAL-CPMG. Proc Intl Soc Mag Reson Med 2015;23:0748.
[21] Kukuk GM, Hittatiya K, Sprinkart AM, et al. Comparison between
modified Dixon MRI techniques, MR spectroscopic relaxometry, and
different histologic quantification methods in the assessment of hepatic
steatosis. Eur Radiol 2015;25:2869–79.
[22] Triplett WT, Baligand C, Forbes SC, et al. Chemical shift-based MRI to
measure fat fractions in dystrophic skeletal muscle. Magn Reson Med
2014;72:8–19.
[23] Bernard CP, Liney GP, Manton DJ, Turnbull LW, Langton CM.
Comparison of fat quantification methods: a phantom study at 3.0T.
J Magn Reson Imaging 2008;27:192–7.
[24] Fischmann A, Hafner P, Gloor M, et al. Quantitative MRI and loss of free
ambulation in Duchenne muscular dystrophy. J Neurol 2013;260:969–74.
[25] Wokke BH, Bos C, Reijnierse M, et al. Comparison of dixon and
T1-weighted MR methods to assess the degree of fat infiltration in
duchenne muscular dystrophy patients. J Magn Reson Imaging 2013;
38:619–24.
[26] Chebrolu VV, Hines CDG, Yu H, et al. Independent estimation of T*2 for
water and fat for improved accuracy of fat quantification. Magn Reson
Med 2010;63:849–57.
[27] Lebel RM, Wilman AH. Transverse relaxometry with stimulated echo
compensation. Magn Reson Med 2010;64:1005–14.
[28] Marty B, Baudin PY, Reyngoudt H, et al. Simultaneous muscle water T2
and fat fraction mapping using transverse relaxometry with stimulated
echo compensation. NMR Biomed 2016;29:431–43.
[29] Yin X, Shah S, Katsaggelos AK, Larson AC. Improved R2* measurement
accuracy with absolute SNR truncation and optimal coil combination.
NMR Biomed 2010;23:1127–36.
[30] Voit T, Topaloglu H, Straub V, et al. Safety and efficacy of drisapersen for
the treatment of Duchenne muscular dystrophy (DEMAND II): an
exploratory, randomised, placebo-controlled phase 2 study. Lancet Neurol
2014;13:987–96.
[31] Willis TA, Hollingsworth KG, Coombs A, et al. Quantitative muscle MRI
as an assessment tool for monitoring disease progression in LGMD2I:
a multicenter longitudinal study. PLoS ONE 2013;8:e70993.
658 A. Mankodi et al. /Neuromuscular Disorders 26 (2016) 650–658
